Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

24.32 +0.70 (+2.94%)
Streaming Delayed Price Updated: 2:03 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+ ↗
Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
Study Reveals LEMS Often Goes Undiagnosed in U.S. Patients with Small Cell Lung Cancer 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold ↗
One key metric to look for in a stock is an 80-plus Relative Strength Rating. ACELYRIN stock hit that mark on Tuesday, with a jump to 81. 
Via Investor's Business Daily
News headline image
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade ↗
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
News headline image
5 Analysts Have This to Say About Catalyst Pharmaceuticals ↗
 
Via Benzinga
News headline image
Where Catalyst Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Catalyst Pharmaceuticals ↗
 
Via Benzinga
News headline image
Exelixis Stock Sees Rising Relative Strength Rating ↗
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now ↗
Although ultra-cheap ideas tend to carry significant risks, these strong buy value stocks offer the endorsement of analysts. 
Via InvestorPlace
News headline image
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing ↗
Although people might not readily recognize these little-known stocks, they offer surprisingly robust upside potential. 
Via InvestorPlace
News headline image
ETF Returns: Mid-Cap Winners And Losers ↗
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on... 
Via Benzinga
News headline image
Truist Securities Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The 7 Best Stocks Under $15 to Buy in June 2023 ↗
While you generally get what you pay for, these best stocks under $15 for June provide compelling opportunities at discount. 
Via InvestorPlace
News headline image
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy? ↗
When evaluating investments, it helps to keep quarterly performance in context. 
Via The Motley Fool
News headline image
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗
Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81. 
Via Investor's Business Daily
News headline image
Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review ↗
The Nasdaq hit a new 2023 high, but not the S&P 500 or Dow Jones. 
Via Investor's Business Daily
News headline image
IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth ↗
Though Catalyst's unadjusted earnings missed forecasts, they grew by triple digits. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales. 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.